Abstract
Background: There is a lack of high quality evidence to inform treatment decisions for patients with locally advanced but non-metastatic oesophagogastric (OGC) adenocarcinoma (Stage IIIb/c). Survival for this group is poor and patient co-morbidities confound decision-making. Treatment may include neoadjuvant therapy and resection, or, non-surgical approaches with chemo/radiotherapy. Treatment impacts quality of life, but may not increase survival. The study aimed to determine the incidence of new patients presenting with locally advanced OGC in the UK and to examine current practice to inform the design of new trials to compare treatment algorithms in this group.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
